Free 24-hour delivery over £75 · Same-day despatchOrder before 2pm - same-day despatch · Free 24-hour delivery over £75
Research use only
All lyophilised (powdered) products and any related items sold by Kovalabs are strictly for scientific research purposes. No dosing guidelines are supplied with any product. We comply with all local regulations governing research-only sales within the United Kingdom. We are not a pharmacy and do not endorse, offer, or provide advice for human or animal consumption. International customers are responsible for checking their own local laws and regulations before purchasing.
You must be 18 or over and purchasing for scientific research only.
By clicking ‘I agree’ you confirm you have read and accepted the terms set out in this disclaimer.
Research use only
· 7 min read
The name lies: "CJC-1295" on its own, strictly, means the long-acting drug - the one with the DAC. The product sold as "CJC-1295 without DAC" is a different molecule with an older, less catchy name: modified GRF 1-29. It is the un-conjugated base - a 29-residue analogue of human growth-hormone-releasing hormone with four deliberate substitutions and no albumin-binding attachment. Stripped of the DAC, it behaves like the short-lived peptide it is. This page covers that base molecule; the conjugated version has its own reference. Kovalabs supplies it strictly as a research reagent; everything below describes what published studies investigated, not any human use, benefit or outcome.
| Compound | CJC-1295 (No DAC) / modified GRF 1-29 |
|---|---|
| Synonyms | Mod GRF (1-29), CJC-1295 without DAC, [D-Ala2,Gln8,Ala15,Leu27]-hGHRH(1-29)NH2 |
| Class / mechanism | GHRH-receptor (GHRHR) agonist; class B / secretin-family GPCR ligand |
| Molecular formula | C152H252N44O42 |
| Molecular weight | 3367.9 g/mol (average) |
| CAS number | 863288-34-0 |
| PubChem CID | 56841945 |
| Supply status | Research use only - not for human or veterinary use |
Modified GRF 1-29 is a 29-residue, C-terminally amidated analogue of human GHRH(1-29). Its sequence carries four substitutions relative to the native hormone - D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27 - changes that the analogue literature associates with resistance to enzymatic cleavage and improved stability over the native fragment. The PubChem record is CID 56841945, molecular formula C152H252N44O42, average molecular weight 3367.9 g/mol, CAS 863288-34-0.
Here is the trap, and it is a real one: the PubChem synonym set for this record is contaminated - it lists both "CJC-1295-no DAC" and "CJC 1295 with DAC" labels against the same entry. Do not identify this compound by name-matching alone. The reliable discriminator is mass: the un-conjugated base is 3367.9 g/mol (C152H252N44O42), whereas the DAC-conjugated drug is about 3647.2 g/mol (C165H269N47O46, CID 91971820) - the roughly 279-unit difference is the Drug Affinity Complex itself. Confirm which molecule a lot is by the mass on its certificate of analysis, not by the label.
| Property | CJC-1295 No DAC (this page) | CJC-1295 with DAC |
|---|---|---|
| Molecular formula | C152H252N44O42 | C165H269N47O46 |
| Molecular weight | 3367.9 g/mol | ~3647.2 g/mol |
| PubChem CID | 56841945 | 91971820 |
| Albumin-binding DAC moiety | Absent | Present (lysine + maleimidopropionyl, ~279 mass) |
| Reported circulating persistence | Short (study-reported PK parameter) | Markedly extended (study-reported PK parameter) |
Modified GRF 1-29 is grouped here by receptor pharmacology, not by any indication. Its target is the growth-hormone-releasing-hormone receptor (GHRHR), a class B (secretin-family) G-protein-coupled receptor on anterior-pituitary somatotroph cells - the same receptor engaged by native GHRH and by sermorelin, the unmodified GHRH(1-29) fragment. In that receptor sense, modified GRF 1-29 is sermorelin's tetrasubstituted, stability-tuned cousin. Jette et al. (Endocrinology, 2005; PMID 15817669) characterised how hGRF(1-29)-based ligands activate the GRF receptor on rat anterior-pituitary cells, the receptor-activation work that underlies the whole CJC-1295 series. The downstream coupling is the standard GHRHR second-messenger cascade (Gs to adenylyl cyclase, raising cAMP); that is a receptor-coupling mechanism, not a physiological outcome.
A receptor-pharmacology point that comes up constantly, because the two are so often studied together: CJC-1295 / modified GRF 1-29 and ipamorelin act on different receptors. Modified GRF 1-29 is a GHRH analogue at the GHRHR; ipamorelin is a ghrelin-mimetic growth-hormone secretagogue at the GHS-R1a (ghrelin) receptor. They sit in the same somatotropic axis but engage distinct receptors with distinct ligand classes - a molecular distinction, stated here as receptor pharmacology and not as any combination, protocol or use.
Dedicated literature on the no-DAC base is limited; most of the CJC-1295 research programme used the DAC-conjugated form (covered on its own page). Each item below is stated as study design and the named endpoint only - no result, effect size or benefit is reproduced, and the form studied is noted.
The honest summary is that modified GRF 1-29 is studied mostly as the un-conjugated reference point for the DAC drug; treat the records above as research context, not as findings to expect.
The notes below are general physicochemical and storage information for bench work only. They are not dosing, administration or use instructions, and nothing here describes a preparation for use in humans or animals.
Modified GRF 1-29 is a synthetic 29-residue, C-terminally amidated peptide, typically supplied as a white lyophilised powder (often the acetate salt). As a hydrophilic, cysteine-free peptide it dissolves readily in aqueous laboratory solvents; gentle swirling is preferred over vigorous shaking to limit shear and foaming. Standard practice: store the sealed lyophilate desiccated, cold and out of light, frozen for long-term storage; reconstitute in an appropriate aqueous solvent and aliquot to avoid freeze-thaw cycles. See the reconstitution guide. The defining bench check is identity by mass: because the no-DAC base (3367.9) and the DAC drug (3647.2) are routinely both called "CJC-1295", the lot certificate of analysis is what confirms which one is in the vial. The conjugated form is covered in the CJC-1295 DAC vs No-DAC reference; the unmodified parent fragment is sermorelin, within the GH-axis research category.
Tier one is solid: the chemistry is not in doubt. Modified GRF 1-29 is a defined 29-residue amidated peptide with verified identifiers (CID 56841945, C152H252N44O42, 3367.9 g/mol, CAS 863288-34-0), and Henninge et al. confirm it is well characterised analytically. Tier two is weaker: the receptor pharmacology rests largely on Jette et al., work done on rat anterior-pituitary cells - a cell in a dish is not a person, and animal receptor-activation does not forecast anything in humans. Tier three is the thinnest of all: the principal randomised human study (Teichman et al.) was conducted on the DAC-conjugated drug, not on this base molecule, so dedicated human data on the no-DAC form is essentially absent. It is not a licensed medicine, and it has not been shown to produce defined outcomes in humans. Curiosity is warranted; certainty is not.
Kovalabs supplies CJC-1295 (No DAC) strictly as a research chemical for laboratory research use only. It is not a medicine, supplement or veterinary product, is not for human or veterinary use, and nothing on this page constitutes a medicinal, therapeutic, efficacy, dosing or human-outcome claim. It has not been evaluated by the MHRA or any comparable regulator for safety or efficacy in humans or animals. The descriptions above are restricted to chemistry and to study designs and endpoint names. Every batch is third-party tested with a certificate of analysis. Full terms are on the research disclaimer page.
"CJC-1295" strictly refers to the long-acting, DAC-conjugated molecule (PubChem CID 91971820, ~3647.2 g/mol). "No DAC" is the un-conjugated base, modified GRF 1-29 (CID 56841945, 3367.9 g/mol) - the same 29-residue GHRH analogue without the albumin-binding Drug Affinity Complex. The roughly 279 g/mol mass difference is the DAC. Confirm which one a lot is by its certificate of analysis.
PubChem CID 56841945, CAS 863288-34-0, molecular formula C152H252N44O42, average molecular weight 3367.9 g/mol, a C-terminally amidated 29-mer with the substitutions D-Ala2, Gln8, Ala15 and Leu27 relative to native GHRH(1-29). Note the PubChem synonym set mixes DAC and no-DAC labels, so verify by mass rather than name.
They are different molecules acting on different receptors. The CJC-1295 peptide (modified GRF 1-29) is a GHRH analogue at the GHRH receptor; ipamorelin is a ghrelin-mimetic growth-hormone secretagogue at the GHS-R1a (ghrelin) receptor. Both sit within the somatotropic axis but engage distinct receptors. This is a receptor-pharmacology distinction only, not a combination, protocol or recommendation for any use.
The growth-hormone-releasing-hormone receptor (GHRHR), a class B secretin-family GPCR on anterior-pituitary somatotrophs - the same receptor as native GHRH and sermorelin. This is a molecular-pharmacology classification, not an indication, and is distinct from the ghrelin/GHS-R pathway of the ghrelin-mimetic secretagogues.
As bench handling of a research reagent only. The lyophilised powder is stored sealed, desiccated, cold and out of light (frozen for long-term storage), and reconstituted in an appropriate aqueous laboratory solvent with gentle swirling, then aliquoted to avoid freeze-thaw cycles. See the reconstitution guide. None of this is a preparation method for any use in humans or animals.
No. It is supplied as a research chemical for laboratory use only, is not approved as a medicine by the MHRA or any comparable regulator, is not for human or veterinary use, and nothing on this page is a medicinal, therapeutic or efficacy claim. See the research disclaimer for full terms.
The publication titles below are the original authors' own titles, reproduced so each citation can be verified against PubMed and the cited DOI. They are not statements, conclusions or claims by Kovalabs, and the body of this page describes each study by its design and endpoint name only.